Second Relapse Common After Initial Melanoma Recurrence on Adjuvant PD-1 Inhibition

Wayne Kuznar
Published: Thursday, Jun 13, 2019
Despite local therapy, many patients with locoregional recurrence of melanoma during or after adjuvant anti–PD-1 therapy relapse again. Moreover, the benefit of second-line adjuvant treatment in this group of patients is unclear.

In reviewing the entire group of 83 patients who received systemic therapy, 29% had subsequent progression and 20 (24%) patients died. At a median follow-up of 7.2 months, the median overall survival from first systemic therapy was 21.3 months.
Owen CN, Larkin JMG, Shoushtari AN, et al. A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy. J Clin Oncol. 2019;37(suppl; abstr 9502). meetinglibrary.asco.org/record/173458/slide.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x